Brief: NeuroCive Out-Licenses Targeted Lhon Therapy To Bridgebio Pharma

Abliva AB

18/06/2018 07:36

June 18 (Reuters) - NeuroVive Pharmaceutical AB  NVP.ST :
    * NEUROVIVE OUT-LICENSES TARGETED LHON THERAPY TO BRIDGEBIO
PHARMA'S NEW SUBSIDIARY FORTIFY THERAPEUTICS
    * LICENSING AGREEMENT FOR THIS PARTICULAR SUBSET OF NVP015
PROGRAM
HAS TOTAL DEAL VALUE OF ABOUT $60 MILLION USD

Source text for Eikon:  ID:nWkr7gDnHw 
Further company coverage:  NVP.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))